Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview

Giuseppe Esposito; Daniele De Filippis; Carla Cirillo; Teresa Iuvone; Elena Capoccia; Caterina Scuderi; Antonio Steardo; Rosario Cuomo; Luca Steardo

doi:10.1002/ptr.4781

journal article Jul 20, 2012

Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview

Giuseppe Esposito

Daniele De Filippis Carla Cirillo

Teresa Iuvone Elena Capoccia Caterina Scuderi

Antonio Steardo Rosario Cuomo Luca Steardo

Phytotherapy Research Vol. 27 No. 5 pp. 633-636 · Wiley

View at Publisher Save 10.1002/ptr.4781

Abstract

This minireview highlights the importance of cannabidiol (CBD) as a promising drug for the therapy of inflammatory bowel diseases (IBD). Actual pharmacological treatments for IBD should be enlarged toward the search for low‐toxicityand low‐cost drugs that may be given alone or in combination with the conventional anti‐IBD drugs to increase their efficacy in the therapy of relapsing forms of colitis. In the past, Cannabis preparations have been considered new promising pharmacological tools in view of their anti‐inflammatory role in IBD as well as other gut disturbances. However, their use in the clinical therapy has been strongly limited by their psychotropic effects. CBD is a very promising compound since it shares the typical cannabinoid beneficial effects on gut lacking any psychotropic effects. For years, its activity has been enigmatic for gastroenterologists and pharmacologists, but now it is evident that this compound may interact at extra‐cannabinoid system receptor sites, such as peroxisome proliferator‐activated receptor‐gamma. This strategic interaction makes CBD as a potential candidate for the development of a new class of anti‐IBD drugs. Copyright © 2012 John Wiley & Sons, Ltd.

Topics

No keywords indexed for this article. Browse by subject →

References

50

[1]

10.1124/jpet.110.168237

[2]

10.1111/j.1476-5381.2011.01589.x

[3]

Aviello G "Chemopreventive effect of the non‐psychotropic phytocannabinoid cannabidiol on experimental colon cancer" J Mol Med

[4]

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis

Francesca Borrelli, Gabriella Aviello, Barbara Romano et al.

Journal of Molecular Medicine 10.1007/s00109-009-0512-x

[5]

10.1208/s12248-009-9084-5

[6]

10.1053/j.gastro.2005.06.018

[7]

10.1038/bjp.2008.177

[8]

10.1053/j.gastro.2011.01.055

[9]

10.1007/s00210-004-0871-3

[10]

10.1111/j.1365-2982.2008.01114.x

[11]

10.1371/journal.pone.0028159

[12]

10.1007/s00535-010-0219-3

[13]

10.1371/journal.pone.0028668

[14]

10.2174/157488412800228875

[15]

10.1007/bf00915771

[16]

10.1157/13097468

[17]

10.2174/156800705774322111

[18]

10.1016/s0140-6736(98)05021-1

[19]

10.2165/00002018-199106030-00005

[20]

10.1111/j.1755-5949.2008.00065.x

[21]

10.1038/sj.bjp.0704293

[22]

10.1007/3-540-26573-2_19

[23]

10.1016/j.phrs.2009.03.008

[24]

10.1016/j.pharmthera.2009.12.005

[25]

10.1111/j.1476-5381.2012.01879.x

[26]

10.1111/j.1476-5381.2010.00791.x

[27]

10.1152/ajpgi.00407.2005

[28]

10.1159/000332079

[29]

10.1097/meg.0b013e328349bb4c

[30]

10.1371/journal.pone.0024031

[31]

10.1111/j.1365-2982.2011.01742.x

[32]

10.1172/jci200419465

[33]

10.1126/science.169.3945.611

[34]

10.1016/s0009-3084(02)00144-5

[35]

Naftali T "Treatment of Crohn's disease with cannabis: an observational study" Isr Med Assoc J (2011)

[36]

10.1124/pr.58.3.2

[37]

10.1007/3-540-26573-2_1

[38]

10.1038/sj.bjp.0706406

[39]

10.1038/sj.bjp.0707442

[40]

10.1038/34178

[41]

10.1002/ibd.20169

[42]

10.1111/j.1476-5381.2011.01238.x

[43]

10.1016/j.jneuroim.2004.10.003

[44]

10.1159/000336871

[45]

10.1016/s0162-3109(98)00041-1

[46]

10.1007/s00109-008-0359-6

[47]

10.1002/j.1552-4604.1981.tb02606.x

[48]

10.1016/0192-0561(91)90160-9

[49]

10.1016/j.clinthera.2008.02.014

[50]

10.1038/sj.bjp.0707486

Cited By

83

Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review

Ze Fu, Peng-Yue Zhao · 2023

Frontiers in Pharmacology

Poly(ethylene glycol)-b-poly(epsilon-caprolactone) nanoparticles as a platform for the improved oral delivery of cannabidiol

Inbar Shreiber-Livne, Liron Sulimani · 2023

Drug Delivery and Translational Res...

Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites

Shamema Nasrin, Christy J.W. Watson · 2021

Drug Metabolism and Disposition

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Natascia Bruni, Carlo Della Pepa · 2018

Molecules

Novel inverse agonists for the orphan G protein-coupled receptor 6

Alyssa S. Laun, Sarah H. Shrader · 2018

Heliyon

Adverse Health Effects of Marijuana Use

Nora D. Volkow, Ruben D. Baler · 2014

New England Journal of Medicine

Metrics

83

Citations

50

References

Details

Published: Jul 20, 2012
Vol/Issue: 27(5)
Pages: 633-636
License: View

Authors

G

Giuseppe Esposito

Department of Physiology and Pharmacology ‘Vittorio Erspamer’, Faculty of Pharmacy and Medicine Sapienza University of Rome Italy

D

Daniele De Filippis

Department of Experimental Pharmacology Faculty of Pharmacy Naples Italy

C

Carla Cirillo

Department of Clinical and Experimental Medicine University Federico II of Naples Naples Italy

T

Teresa Iuvone

Department of Experimental Pharmacology Faculty of Pharmacy Naples Italy

E

Elena Capoccia

Department of Physiology and Pharmacology ‘Vittorio Erspamer’, Faculty of Pharmacy and Medicine Sapienza University of Rome Italy

C

Caterina Scuderi

Department of Physiology and Pharmacology ‘Vittorio Erspamer’, Faculty of Pharmacy and Medicine Sapienza University of Rome Italy

A

Antonio Steardo

Department of Physiology and Pharmacology ‘Vittorio Erspamer’, Faculty of Pharmacy and Medicine Sapienza University of Rome Italy

R

Rosario Cuomo

Department of Clinical and Experimental Medicine University Federico II of Naples Naples Italy

L

Luca Steardo

Department of Physiology and Pharmacology ‘Vittorio Erspamer’, Faculty of Pharmacy and Medicine Sapienza University of Rome Italy

Cite This Article

Giuseppe Esposito, Daniele De Filippis, Carla Cirillo, et al. (2012). Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Phytotherapy Research, 27(5), 633-636. https://doi.org/10.1002/ptr.4781

Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview

You May Also Like